Estrogen is generally considered to maintain bone mass through suppression of bone resorption. We have previously demonstrated that administration of pharmacologic doses of estrogen increases bone formation in ovary-intact rats. To assess the effects of physiological concentrations of estrogen on bone formation, estrogen was administered to ovariectomized rats in which bone resorption was suppressed by the bisphosphonate 3-amino-1-hydroxypropylidene-1-bisphosphonate (AHPrBP). Animals receiving exogenous 17 beta-estradiol (E2) (1, 10, and 100 micrograms/kg daily for 17 d) showed a dosedependent increase in trabecular bone volume of 1.9, 25.8, and 43.6%, respectively, compared with those rats treated with AHPrBP alone. The increase in bone volume was associated with an increase in bone formation in E2-treated animals, in which bone resorption had been almost completely suppressed by AHPrBP. Neither ovariectomy, AHPrBP, nor E2 treatment had a significant effect on the volume or rate of formation of cortical bone. Thus, the increased bone resorption, which is a consequence of estrogendeficiency, entrains increased bone formation, which masks a simultaneous reduction in estrogen-dependent bone formation. Therefore, in addition to the nonspecific effect of estrogen to depress formation via coupling, we have identified a specific effect of estrogen to increase formation independent of coupling. Thus it appears that estrogen maintains bone volume not only through inhibition of bone resorption, but also through stimulation of bone formation.
Introduction
A reduction in estrogen levels after menopause is thought to be responsible for the accelerated bone loss (1, 2) and increased risk of sustaining osteoporotic fractures (3, 4) found in postmenopausal women. The bone loss of estrogen deficiency is attributable to an increase in bone resorption, together with a smaller increase in bone formation: indices of both formation and resorption are suppressed by replacement concentrations of estrogen, and further bone loss is prevented (5) (6) (7) (8) . Thus, estrogen is generally considered to maintain bone mass through an antiresorptive mechanism. This antiresorptive effect has recently been shown to be explicable as a direct effect of estrogen on bone (9, 10) , in which estrogen induces cells ofthe osteoblastic lineage to inhibit osteoclastic bone resorption (1 1).
The effects of estrogen on bone formation seem paradoxical for a hormone that maintains bone mass, but are generally presumed to be the consequence of the mechanism that couples bone formation to bone resorption, such that suppression of bone resorption also suppresses bone formation (12) . These resorption-induced changes in bone formation may mask an independent and distinct effect ofestrogen on bone formation.
We have recently found that administration of pharmacological doses of estrogen, sufficient to raise concentrations to those seen in late pregnancy, increase bone formation above the rates observed in rats with physiological (nonpregnant) estrogen levels (13) . In this study, we assess the effects of physiological levels of estrogen on bone formation. To mies was confirmed by absence of ovaries and atrophy of uteri in rats not given estrogen therapy. Uteri were removed and weighed. Serum levels ofE2 were measured by RIA (Coat-a-Count; Diagnostic Products Ltd., Abingdon, UK). The lower limit of sensitivity of this assay is 8 pg/ml E2. The right tibia was removed and freed of soft tissue. It was then divided into an 8-mm diaphyseal section just proximal to the distal tibio-fibular anastomosis, and a second section that comprised the proximal metaphysis and epiphysis. These were fixed in 70% alcohol for 48 h, dehydrated through graded alcohols and embedded undecalcified in London resin (London Resin Co. Ltd, Basingstoke, UK). Longitudinal sections of the proximal metaphysis 5 M thick were cut and stained with von Kossa and toluidine blue. Unstained sections 12 Mm thick were also cut. Cross sections ofthe tibial shaft were cut with a low speed diamond saw at 250 Mm and hand ground to 100-120 Mm. Unstained sections for assessing fluorochrome labeling and sections stained with toluidine blue were examined.
Bone histomorphometry was performed using a light microscope linked to an Optomax (Analytical Measuring System Ltd., Cambridge, UK). Bone volume and surface parameters were obtained by tracing relevant surfaces with a cursor on the video screen image using an automated and semiautomated mode, respectively. All sections were examined blind.
Bone volume of the proximal metaphyseal cancellous bone was measured on three nonconsecutive serial sections stained with von Kossa at a magnification of 100. A standard area of three adjacent frames (0.78 mm2 each) in the vertical axis situated at least 1 mm from the growth plate to exclude the primary spongiosa was used (8, 10) . Bone volume was defined as the percentage of metaphyseal bone area that consisted of bone. Surface parameters were measured in two sections stained with toluidine blue at a magnification of 200. A standard area of 18 frames (3 parallel to the growth plate and 6 in the vertical axis), measuring 0.18 mm2 each, located in the secondary spongiosa in a corresponding area to that used for assessing bone volume, was used. . Fluorochrome measurements were made on unstained 10-15-Mm-thick sections of the same area. Longitudinal bone growth was derived as follows. The distance between the tetracycline band that parallels the growth plate and the growth plate-metaphyseal junction was measured, and divided by the time interval between the tetracycline label and death. The percentage of trabecular surface with a double fluorochrome label was measured as for the other surface parameters. Mineral apposition rate was the interlabel distance divided by the time interval (days) between their administration. The bone formation rate (tissue level, total surface referent) was obtained from the product of the mineral apposition rate and the percentage of trabecular surface covered in double label. Values for the apposition rate were not corrected for the obliquity ofplane of section of trabecular bone.
The parameters measured on the shaft cross sections made on two stained and two unstained sections were the cross-sectional area, medullary area, cortical area (cross-sectional area minus medullary area), percentage of double-labeled surface on the periosteal and cortico-endosteal surfaces, and interlabel distances on these two envelopes. The mineral apposition rates and bone formation rates were calculated in a similar way to the metaphyseal trabecular bone.
Results from biochemical and histomorphometric analysis are expressed as the mean±SEM. Statistical analysis was performed by Fisher's least significant difference method for multiple comparisons in a one-way analysis of variance with Apple software (Statview 1.02; Abacus Concepts Inc., Cupertino, CA). Statistical significance was considered at P < 0.05.
Results

Systemic changes
At the end of the experiment, the ovariectomized animals not on E2 treatment showed an increase in body weight compared with controls despite pair feeding. The uteri of these animals were markedly atrophic, apart from those given E2, which restored the size to that of controls (Table II) . The serum E2 measurements also confirmed the effect of ovariectomy and that of estrogen treatment.
Bone histomorphometry Proximal metaphysis. Ovariectomy caused a substantial decrease in bone volume, which was prevented by AHPrBP (Fig.  1) . We found that the bone volume was increased by 1.9, 25.8, and 43.6% in animals treated with 1, 10, and 100 Mg/kg E2, respectively, compared with ovariectomized animals given AHPrBP alone (Fig. 1) . This increase in bone volume with the two higher doses was significant compared with the bone volume of rats treated with AHPrBP alone.
Bone turnover was increased by ovariectomy, as reflected by a twofold increase in the double-labeled bone surface. This was strongly inhibited by administration of AHPrBP (Fig. 2) . The increase in bone volume in animals treated with E2 was due to a marked increase in the mineral apposition rate and percentage ofdouble-labeled surface, both ofwhich were significantly different in the groups treated with 10 and 100 jig E2 compared with AHPrB? alone ( rate was significantly greater in animals treated with 100 ug/kg E2 than animals treated with AHPrBP alone (Fig. 2) . The osteoblast surface showed a parallel increase in ovariectomized animals, although this did not reach statistical significance. This was markedly suppressed with AHPrBP (Table   III) . The osteoblast surface in animals treated with 100 ,gg/kg E2 was increased compared with those treated with AHPrBP alone, but this was not statistically significant. Hence the osteoblast surface appears to be a less sensitive parameter for bone formation than double-labeled surface. The osteoclast surface and number of osteoclasts per millimeter of bone surface was increased in ovariectomized animals, and decreased in animals treated with AHPrBP. There were no statistically significant differences in osteoclast number or surface between animals treated with E2 and those treated with AHPrBP alone.
Nonmetaphyseal bone. Ovariectomy and AHPrBP treatment did not appear to affect the longitudinal growth rate, but this was suppressed in a dose-dependent manner in E2-treated animals, (Table III) . Although AHPrBP suppressed bone formation at the proximal metaphysis, we saw no effect on the periosteal and cortico-endosteal double-labeled surfaces or bone formation rate (Table IV) . Similarly, there was no significant difference between E2-treated animals and those treated with AHPrBP alone with respect to these parameters (data not shown).
Discussion one tormation
It is well established that in ovariectomized and postmenopausal women there is an increase in bone turnover, associated with increased bone resorption and an increase in bone formation insufficient to compensate for increased bone resorption (5, 6, 14-16). A similar sequence has been described in ovariectomized rats (7, 8) . In accord with these observations, we found that the ovariectomized rats showed a substantial loss of metaphyseal bone despite an increase in bone formation.
In those ovariectomized rats that were also given AHPrBP, which inhibits bone resorption (17), bone loss was prevented. Metaphyseal bone formation was also inhibited. Suppression of bone resorption by bisphosphonates has been reported by others to inhibit bone formation in ovariectomized rats (18) and it is well established that suppression of bone resorption a generally causes a reduction in bone formation (19 proximal metaphysis is estrogen dependent, and that estrogen, at physiological concentrations, exerts an anabolic effect on bone at this site. It is possible, however, that a component of the increase in bone volume may be an additive inhibition of bone resorption by E2 and AHPrBP. Despite the dose-dependent anabolic effect of estrogen in the physiological range, bone formation rates were higher in ovariectomized rats than in animals administered even doses adequate for replacement. Consequently, after ovariectomy, the stimulation of bone formation consequent on increased bone resorption exceeds, and thus masks, the simultaneous reduction in estrogen-dependent bone formation. It appears that estrogen maintains bone mass not only through an antiresorptive effect but also through stimulation ofbone formation.
We also noted that E2 inhibited longitudinal bone growth due to a reduction in the growth of epiphyseal cartilage, as found by others (8, 20) . The question arises of whether decreased longitudinal growth could contribute to the increased Although estrogen clearly has a potent antiresorptive effect, which has made a separate anabolic effect difficult to identify, it seems reasonable that a hormone implicated in the maintenance ofbone mass should be both anabolic and anticatabolic. In fact, there is evidence from other sources that supports an anabolic role for estrogen: ovariectomy in Beagle dogs has been found to reduce mean wall thickness (21) , and estrogen increases proliferation and collagen production by bone cells in vitro (22, 23) .
However, although estrogen is a potent antiresorptive agent, resorption clearly occurs in the presence of intact ovarian function, and can be inhibited further by agents such as bisphosphonates (17) . This is consistent with our own results, in which AHPrBP maintained bone volume despite lack of detectable bone formation in ovariectomized rats; restoration ofanabolism by estrogen replacement then induced a considerable increase in bone volume. This implies that suppression of resorption beyond that induced by physiological levels ofestrogen, together with restoration of anabolism through estrogen replacement, may have a greater effect on bone volume than either bisphosphonate or estrogen alone in estrogen-deficiency states.
The anabolic effect of estrogen was achieved by a combination of an increase in osteoblast recruitment, as judged by an increase in the extent of trabecular surfaces showing double fluorochrome labeling, and an increase in the productivity of individual osteoblasts, as evidenced by an increase in the mineral apposition rate by E2 with AHPrBP, compared to AHPrBP alone. Although both were increased, the pattern ofresults over the dose range of E2 used suggests that increased recruitment may be the dominant mechanism by which E2 induces anabolism. This question is currently being further addressed. Osteoblast surfaces broadly reflected changes in double-labeled surfaces, but the proportion of bone surfaces lined by osteoblasts was less than that showing double label. This may be due to caution in counting as osteoblastic only those surfaces on which we were convinced that osteoblasts were present. A similar relationship between osteoblastic and double-labeled surfaces has been noted by other investigators (8) . Double label is more objective and reliable, and we have based our conclusions largely on this.
The anabolic effect of estrogen seems to be specific for the metaphysis: no significant effect was observed at the diaphysis. This is consistent with the results of others who have found no decrease in cortical bone area in the diaphysis of ovariectomized rats, while the metaphysis becomes osteopenic following ovariectomy (24, 25) , and also is consistent with the generally different responsiveness of dynamic histomorphometric parameters in metaphyseal and cortical bone to ovariectomy and hormone replacement (7, (25) (26) (27) (28) . Bone also accumulates in the metaphysis after PTH therapy (29, 30), during high dose estrogen therapy (31) (32) (33) (34) , and before egg production in birds (35) . It is intriguing to speculate that estrogen may induce and maintain bone at this site as an estrogen-dependent quantum of bone (24) that is available as a metabolic reserve.
Although there is the reservation that the skeleton ofthe rat does not necessarily behave in a similar manner to the trabecular bone of man, at least some remodeling occurs (36) , and the rat shows a similar skeletal response to ovariectomy and estrogen replacement (7, 8) . It therefore seems possible that the anabolic role we have identified for estrogen, in addition to its known antiresorptive role, may be of relevance to the mechanisms by which bone is lost in estrogen-deficient states and to therapeutic approaches to this bone loss in women.
